|
FY2026
12 months to Jan 31, 2026
|
FY2025
12 months to Jan 31, 2025
|
FY2024
12 months to Jan 31, 2024
|
FY2023
12 months to Jan 31, 2023
|
FY2022
12 months to Jan 31, 2022
|
|
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of Revenue | |||||
| Gross Profit | |||||
| Costs and Expenses: | |||||
| Selling and Marketing | |||||
| Research and Development | |||||
| General and Administrative | |||||
| Goodwill Impairment | |||||
| Operating Expenses | |||||
| Operating Income (Loss) | |||||
| Other Income (Expense): | |||||
| Interest Expense | |||||
| Gain (Loss) on Foreign Currency Transactions | |||||
| Gain on Extinguishment of Debt – PPP Loan | |||||
| Loss on Disposal of Assets | |||||
| Other, net | |||||
| Total Other Income (Expense) | |||||
| Income (Loss) before Income Taxes | |||||
| Income Tax Expense (Benefit) | |||||
| Net Income (Loss) | |||||
| Net Income (Loss) Per Common Share-Basic | |||||
| Net Income (Loss) Per Common Share-Diluted | |||||
| Weighted Average Number of Common Shares Outstanding—Basic | |||||
| Dilutive Effect of Common Stock Equivalents | |||||
| Weighted Average Number of Common Shares Outstanding—Diluted |
Loading...